About the Company
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TTNP News
Titan Pharmaceuticals Inc.
TITAN PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. Even though sales decreased ...
Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval
TheStreet Ratings has this to say about the recommendation: We rate TITAN PHARMACEUTICALS INC as a Sell with a ratings score of E+. This is based on the dominance of unfavorable investment ...
Titan Pharmaceuticals Reports Full Year and Fourth Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 15, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select ...
Titan Pharmaceuticals Inc TTNP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Titan Pharmaceuticals Inc TN70
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Titan Pharmaceuticals, Inc. Common Stock (TTNP)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
TTNP Titan Pharmaceuticals, Inc.
The security has traded for less than one year There is no Wall Street analyst coverage The security is a closed-end fund or a mortgage REIT The security is listed on a non-US exchange The ...
Titan Pharmaceuticals Inc (TTNP)
PDUFA date extended to May 2016In January, an FDA Advisory Committee recommended approval of Titan Pharmaceuticals Inc (O:TTNP) lead product, Probuphine, the first long-acting form ...
Titan Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics utilizing its long-term drug delivery platform, ProNeura, for the treatment of select chronic ...
Titan Pharmaceuticals Inc (TTNP)
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Utilities, Technology and Healthcare sectors propelled shares higher. At the close in NYSE,... Investing.com – U.S.
Titan Pharmaceuticals, Inc. (TTNP)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...